The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.
Exploring BTK Degraders in CLL/SLL Management
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Wins EU Approval for Previously Treated, HER2+ Metastatic Solid Tumors
2
Elisrasib Yields Durable Responses in Pretreated KRAS G12C–Mutant NSCLC Regardless of Prior G12C Inhibitor Use
3
FDA Issues CRL to PET Diagnostic Imaging Kit for Gallium-68 Edotreotide in SSTR+ NETs
4
Dr Thomas on the Efficacy of First-Line Ipatasertib Plus Pembrolizumab in HNSCC
5